Aegle Therapeutics is developing extracellular vesicle therapy to accelerate regenerative healing while reducing or eliminating scarring. We believe that our EVs will function similar to their host stem cells and effect neuronal regeneration, angiogenesis, re-pigmentation and hair follicle growth in patients with severe wounds including burns and chronic pressure ulcers. We are also targeting the rare pediatric disease epidermolysis bullosa given the regenerative effects of EVs and their propensity to deliver critical proteins to diseased cells.
Aegle filed an IND with the FDA to treat burns using allogeneic sourced EVs. We anticipate being in the clinic with our EV Therapy in 2018.